文献速递糖尿病

中国糖尿病结局模型在2型糖尿病长期并发症中的开发与验证:香港糖尿病登记处的应用

Development and Validation of the Patient-Level Chinese Diabetes Outcome Model on Long-term Complications in Type 2 Diabetes: An Application of the Hong Kong Diabetes Register.
PubMed 文献 · Diabetes Care · 2025-01-01

基于香港糖尿病登记处前瞻性队列(n=21,453,中位随访7.9年,166,433患者年)开发中国糖尿病结局模型(CDOM),并在全港回顾性队列(n=176,120,随访7.2年,953,523患者年)外部验证。模型预测首发和复发事件内部验证C统计量0.740-0.941,外部验证0.758-0.932;癌症对应C统计量分别为0.664和0.661。结论认为CDOM是预测中国2型糖尿病患者长期结局的稳健工具。

要点

  • CDOM基于香港糖尿病登记处21,453例2型糖尿病患者开发,中位随访7.9年。
  • 外部验证队列176,120例,随访7.2年,首发和复发事件C统计量0.758-0.932。
  • 癌症预测C统计量内部0.664、外部0.661,低于其他结局。

核心结论

  • CDOM基于全面登记数据和长期随访开发,是预测中国2型糖尿病患者长期结局的稳健工具。
  • 模型可识别患者亚组以优化研究设计、制定量身定制的新治疗策略、为政策提供信息并指导实践以提高糖尿病照护的成本效益。

研究设计与样本

  • CDOM使用前瞻性香港糖尿病登记处队列开发(n=21,453;中位随访7.9年;166,433患者年)。
  • 采用回顾性全港队列进行外部验证,该队列为就诊于香港 publicly funded 糖尿病中心和社区诊所的中国2型糖尿病患者(n=176,120;随访7.2年;953,523患者年)。

主要发现

  • CDOM预测首发和复发事件,内部验证(校准后C统计量=0.740-0.941)和外部验证(校准后C统计量=0.758-0.932)性能满意。
  • 癌症对应的C统计量内部验证为0.664,外部验证为0.661。
  • 亚组分析显示内部验证(校准后C统计量=0.632-0.953)和外部验证(校准后C统计量=0.598-0.953)性能一致。

临床怎么用

  • 模型可识别患者亚组以优化研究设计、制定量身定制的新治疗策略、为政策提供信息并指导实践以提高糖尿病照护的成本效益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patient-level simulation models, mainly developed in Western populations, capture complex interactions between risk factors and complications to predict the long-term effectiveness and cost-effectiveness of novel treatments and identify high-risk subgroups for personalized care. However, incidence of outcomes varies significantly by ethnicity and region. We used high-quality, patient-level register data to develop the Chinese Diabetes Outcomes Model (CDOM) for predicting incident and recurrent events in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: The CDOM was developed using the prospective Hong Kong Diabetes Register (HKDR) cohort (n = 21,453; median follow-up duration, 7.9 years; 166,433 patient-years). It was externally validated with a retrospective territory-wide cohort of Chinese patients with T2D attending Hong Kong publicly funded diabetes centers and community clinics (n = 176,120; follow-up duration, 7.2 years; 953,523 patient-years). RESULTS: The CDOM predicted first and recurrent events with satisfactory performance during internal (C-statistic = 0.740-0.941) and external (C-statistic = 0.758-0.932) validation after calibration. The respective C-statistic values for cancer were 0.664 and 0.661. Subgroup analysis showed consistent performance during internal (C-statistic = 0.632-0.953) and external (C-statistic = 0.598-0.953) validation after calibration. CONCLUSIONS: The CDOM, developed using comprehensive register data with long-term follow-up, is a robust tool for predicting long-term outcomes in Chinese patients with T2D. The model enables the identification of patient subgroups to augment study design and develop tailored novel treatment strategies, inform policy, and guide practice to improve cost-effectiveness of diabetes care.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lau ESH, Luk AOY, Lim LL, et al. Development and Validation of the Patient-Level Chinese Diabetes Outcome Model on Long-term Complications in Type 2 Diabetes: An Application of the Hong Kong Diabetes Register. Diabetes Care. 2025. PMID: 39998909. doi:10.2337/dca24-0069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。